The Hydration Pharmaceuticals Co (ASX:HPC) YoY EBITDA Growth: 53.85% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is The Hydration Pharmaceuticals Co YoY EBITDA Growth?

The Hydration Pharmaceuticals Co ASX:HPC YoY EBITDA Growth is 53.85% as of Dec. 2025. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. The Hydration Pharmaceuticals Co's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 53.85%.

The Hydration Pharmaceuticals Co's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.01.

The Hydration Pharmaceuticals Co YoY EBITDA Growth Related Terms

The Hydration Pharmaceuticals Co YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for The Hydration Pharmaceuticals Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Hydration Pharmaceuticals Co YoY EBITDA Growth Chart

The Hydration Pharmaceuticals Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -69.09 54.84 50.00 47.62

The Hydration Pharmaceuticals Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only 67.16 57.89 40.91 37.50 53.85

The Hydration Pharmaceuticals Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

The Hydration Pharmaceuticals Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.011--0.021)/ | -0.021 |
=47.62 %

The Hydration Pharmaceuticals Co's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.006--0.013)/ | -0.013 |
=53.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 53.85% mean?
The Hydration Pharmaceuticals Co (ASX:HPC) has a YoY EBITDA Growth of 53.85% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for The Hydration Pharmaceuticals Co and its competitors.
Is The Hydration Pharmaceuticals Co's YoY EBITDA Growth too high?
The Hydration Pharmaceuticals Co's current YoY EBITDA Growth is 53.85%.
How does The Hydration Pharmaceuticals Co's YoY EBITDA Growth compare to SYY and USFD?
The Hydration Pharmaceuticals Co's YoY EBITDA Growth of 53.85% can be compared against companies in the Retail - Defensive industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Retail - Defensive company?
A good YoY EBITDA Growth depends on the Retail - Defensive industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for The Hydration Pharmaceuticals Co and its competitors. The Hydration Pharmaceuticals Co's current YoY EBITDA Growth is 53.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Hydration Pharmaceuticals Co stock overvalued right now?
The Hydration Pharmaceuticals Co (ASX:HPC) has a current YoY EBITDA Growth of 53.85%. The current YoY EBITDA Growth is 53.85%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For The Hydration Pharmaceuticals Co (ASX:HPC), the current YoY EBITDA Growth is 53.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Hydration Pharmaceuticals Co Business Description

Address 6 Palmer Parade, Level 2, Cremorne, Melbourne, VIC, AUS, 3121
The Hydration Pharmaceuticals Co Ltd is a consumer products company that markets and sells a range of liquid, tablet and powder Healthy Hydration Solutions products into the USA market, under the Hydralyte brand. Hydralyte collates and translates consumer insights and needs into developing and delivering quality hydration products to market. The Company's business model is an asset light, flexible production model that allows it to outsource manufacturing and packaging to appropriate suppliers.